nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

01.11.2014 | Review

Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD)

verfasst von: Wolfgang Retz, Petra Retz-Junginger

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent mental disorder of childhood, which often persists in adulthood. Methylphenidate (MPH) is one of the most effective medications to treat ADHD, but also few adult patients show no sufficient response to this drug. In this paper, we give an overview regarding genetic, neuroimaging, clinical and other studies which have tried to reveal the reasons for non-response in adults with ADHD, based on a systematic literature search. Although MPH is a well-established treatment for adults with ADHD, research regarding the prediction of treatment outcome is still limited and has resulted in inconsistent findings. No reliable neurobiological markers of treatment response have been identified so far. Some findings from clinical studies suggest that comorbidity with substance use disorders and personality disorders has an impact on treatment course and outcome. As MPH is widely used in the treatment of adults with ADHD, much more work is needed regarding positive and negative predictors of long-term treatment outcome in order to optimize the pharmacological treatment of adult ADHD patients.

Polanczyk G, Rohde LA (2007) Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 20:386–392PubMedCrossRef

Fayyad J, De Graf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, De Girolamo G, Haro JM, Karam EG, Lara C, Lépine JP, Ormel J, Posada-Villa J, Zaslavsky AM, Jin R (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190:402–409PubMedCrossRef

Barkley RA, Fischer M, Smallish L, Fletcher K (2006) Young adult outcome of hyperactive children; adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 45:92–202CrossRef

Stein MA (2004) Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments. Am J Manag Care 10:S89–S98PubMed

Retz W, Retz-Junginger P, Thome J, Rösler M (2011) Pharmacological treatment of adult ADHD in Europe. World J Biol Psychiatry 12(Suppl 1):89–94PubMedCrossRef

Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK (2007) A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68:93–101PubMedCrossRef

Rösler M, Fischer R, Ammer R, Ose C, Retz W (2009) A randomised, placebo-controlled, 24-week, study of low dose extended-release methylphenidate in adults with attentiondeficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259:120–129PubMedCrossRef

Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, Philipsen A, Herpertz S, Ammer R (2010) Twenty-for-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry 11:709–718PubMedCrossRef

Marchant BK, Reimherr FW, Robison RJ, Olsen JL, Kondo DG (2011) Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. J Atten Disord 15:295–304PubMedCrossRef

10.

Spencer TJ, Adler LA, Weisler RH, Youcha SH (2008) Triplebead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry 69:1437–1448PubMedCrossRef

11.

Wender PH, Reimherr FW, Marchant BK, Sanford ME, Czajkowski LA, Tomb DA (2011) A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord 15:35–45CrossRef

12.

Huss M, Ginsberg Y, Tvedten T, Arngrim T, Philipsen A, Carter K, Chen CW, Kumar V (2014) Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Adv Ther 31:44–65PubMedCrossRefPubMedCentral

13.

Retz W, Rösler M, Ose C, Scherag A, Alm B, Philipsen A, Fischer R, Ammer R (2012) Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatry 13:48–59PubMedCrossRefPubMedCentral

14.

Rösler M, Ginsberg Y, Arngrim T, Adamou M, Niemelä A, Dejonkheere J, van Oene J, Schäuble B (2013) Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attentiondeficit/hyperactivity disorder treated with OROS methylphenidate. World J Biol Psychiatry 14:282–290PubMedCrossRef

15.

Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J (2004) Meta-analysis of the efficacy of methylphenidate for treating adult attentiondeficit/hyperactivity disorder. J Clin Psychopharmacol 24:24–39PubMedCrossRef

16.

Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S (2009) Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733–744PubMedCrossRef

17.

Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I (2009) Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 12:1137–1147PubMedCrossRef

18.

Faraone SV, Glatt SJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71:754–763PubMedCrossRef

19.

Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, Casas M (2011) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25:157–169PubMedCrossRef

20.

Ebert D, Krause J, Roth-Sackenheim C, the DGPPN Expert Committee (2003) ADHD in adulthood—guidelines based on expert consensus with DGPPN support. Nervenarzt 74:939–946PubMed

21.

Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S, British Association for Psychopharmacology (2007) Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 21:10–41PubMedCrossRef

22.

National Institute for Health and Clinical Excellence (2008) Attention deficit hyperactivity disorder: pharmacological and psychological interventions in children, young people and adults. www.NICE.org.uk

23.

Scassellati C, Bonvicini C, Faraone SV, Gennarelli M (2012) Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. J Am Acad Child Adolesc Psychiatry 51:1003–1019PubMedCrossRef

24.

Franke B, Faraone SV, Asherson P, Buitelaar J, Bau CH, Ramos-Quiroga JA, Mick E, Grevet EH, Johansson S, Haavik J, Lesch KP, Cormand B, Reif A; International Multicentre persistent ADHD Collaboration (2012) The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 17:960–987CrossRef

25.

Zhou K, Dempfle A, Arcos-Burgos M, Bakker SC, Banaschewski T, Biederman J, Buitelaar J, Castellanos FX, Doyle A, Ebstein RP, Ekholm J, Forabosco P, Franke B, Freitag C, Friedel S, Gill M, Hebebrand J, Hinney A, Jacob C, Lesch KP, Loo SK, Lopera F, McCracken JT, McGough JJ, Meyer J, Mick E, Miranda A, Muenke M, Mulas F, Nelson SF, Nguyen TT, Oades RD, Ogdie MN, Palacio JD, Pineda D, Reif A, Renner TJ, Roeyers H, Romanos M, Rothenberger A, Schäfer H, Sergeant J, Sinke RJ, Smalley SL, Sonuga-Barke E, Steinhausen HC, van der Meulen E, Walitza S, Warnke A, Lewis CM, Faraone SV, Asherson P (2008) Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B:1392–1398PubMedCrossRefPubMedCentral

26.

Retz W, Thome J, Blocher D, Baader M, Rösler M (2002) Association of attention deficit hyperactivity disorder-related psychopathology and personality traits with the serotonin transporter promoter region polymorphism. Neurosci Lett 319:133–136PubMedCrossRef

27.

Retz W, Rösler M, Kissling C, Wiemann S, Hünnerkopf R, Coogan A, Thome J, Freitag C (2008) Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. J Neural Transm 115:323–329PubMedCrossRef

28.

de Azeredo LA, Rovaris DL, Mota NR, Polina ER, Marques FZ, Contini V, Vitola ES, Belmonte-de-Abreu P, Rohde LA, Grevet EH, Bau CH (2014) Further evidence for the association between a polymorphism in the promoter region of SLC6A3/DAT1 and ADHD: findings from a sample of adults. Eur Arch Psychiatry Clin Neurosci 264:401–408PubMedCrossRef

29.

Reif A, Jacob CP, Rujescu D, Herterich S, Lang S, Gutknecht L, Bähne CG, Strobel A, Freitag CM, Giegling I, Romanos M, Hartmann A, Rösler M, Renner TJ, Fallgatter AJ, Retz W, Ehlis AC, Lesch KP (2009) Influence of functional variant of neuronal nitric oxide synthase on impulsive behaviors in humans. Arch Gen Psychiatry 66:41–50PubMedCrossRef

30.

Weber H, Scholz CJ, Jacob CP, Heupel J, Kittel-Schneider S, Erhardt A, Hempel S, Schmidt B, Kiel T, Gessner A, Lesch KP, Reif A (2014) SPOCK3, a risk gene for adult ADHD and personality disorders. Eur Arch Psychiatry Clin Neurosci 264:409–421PubMedCrossRef

31.

Li Z, Chang SH, Zhang LY, Gao L, Wang J (2014) Molecular genetic studies of ADHD and its candidate genes: a review. Psychiatr Res 219:10–24CrossRef

32.

Lee HY, Song GG (2014) Genome-wide pathway analysis in attention-deficit/hyperactivity disorder. Neurol Sci 35:1189–1196PubMedCrossRef

33.

Retz W, Freitag CM, Retz-Junginger P, Wenzler D, Schneider M, Kissling C, Thome J, Rösler M (2008) A functional serotonin transporter promoter gene polymorphism increases ADHD symptoms in delinquents: interaction with adverse childhood environment. Psychiatr Res 158:123–131CrossRef

34.

Getahun D, Rhoads GG, Demissie K, Lu SE, Quinn VP, Fassett MJ, Wing DA, Jacobsen SJ (2013) In utero exposure to ischemic-hypoxic conditions and attention-deficit/hyperactivity disorder. Pediatrics 131:e53–e61PubMedCrossRef

35.

Bruxel EM, Akutagava-Martins GC, Salatino-Oliveira A, Contini V, Kieling C, Hutz MH, Rohde LA (2014) ADHD pharmacogenetics across the life cycle: new findings and perspectives. Am J Med Genet B Neuropsychiatr Genet 165B:263–282PubMedCrossRef

36.

Froehlich TE, McGough JJ, Stein MA (2010) Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 24:99–117PubMedCrossRefPubMedCentral

37.

Polanczyk G, Bigarella MP, Hutz MH, Rohde LA (2010) Pharmacogenetic approach for a better drug treatment in children. Curr Pharm Des 16:2462–2473PubMedCrossRef

38.

Contini V, Victor MM, Bertuzzi GP, Salgado CA, Picon FA, Grevet EH, Rohde LA, Belmonte-de-Abreu P, Bau CH (2012) No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD. J Clin Psychopharmacol 32:820–823PubMedCrossRef

39.

Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV (2008) Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B:1412–1418PubMedCrossRef

40.

Evans KC, Dougherty DD, Pollack MH, Rauch SL (2006) Using neuroimaging to predict treatment response in mood and anxiety disorders. Ann Clin Psychiatry 18:33–42PubMedCrossRef

41.

Shaw P, Lerch J, Greenstein D, Sharp W, Clasen L, Evans A, Giedd J, Castellanos FX, Rapoport J (2006) Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attentiondeficit/hyperactivity disorder. Arch Gen Psychiatry 63:540–549PubMedCrossRef

42.

Semrud-Clikeman M, Filipek PA, Biederman J, Steingard R, Kennedy D, Renshaw P, Bekken K (1994) Attention-deficit hyperactivity disorder: magnetic resonance imaging morphometric analysis of the corpus callosum. J Am Acad Child Adolesc Psychiatry 33:875–881PubMedCrossRef

43.

Filipek PA, Semrud-Clikeman M, Steingard RJ, Renshaw PF, Kennedy DN, Biederman J (1997) Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. Neurology 48:589–601PubMedCrossRef

44.

Mackie S, Shaw P, Lenroot R, Pierson R, Greenstein DK, Nugent TF 3rd, Sharp WS, Giedd JN, Rapoport JL (2007) Cerebellar development and clinical outcome in attention deficit hyperactivity disorder. Am J Psychiatry 164:647–655PubMedCrossRef

45.

Skokauskas N, Hitoshi K, Shuji H, Frodl T (2013) Neuroimaging markers for the prediction of treatment response to Methylphenidate in ADHD. Eur J Paediatr Neurol 17:545–551CrossRef

46.

Krause J, la Fougere C, Krause KH, Ackenheil M, Dresel SH (2005) Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur Arch Psychiatry Clin Neurosci 255:428–431PubMedCrossRef

47.

la Fougère C, Krause J, Krause KH, Josef Gildehaus F, Hacker M, Koch W, Hahn K, Tatsch K, Dresel S (2006) Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl Med Commun 27:733–737PubMedCrossRef

48.

van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB (2002) Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 159:309–312PubMedCrossRef

49.

Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD (2003) Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 30:306–311PubMedCrossRef

50.

Ilgin N, Senol S, Gucuyener K, Gokcora N, Sener S (2001) Is increased D2 receptor availability associated with response to stimulant medication in ADHD. Dev Med Child Neurol 43:755–760PubMedCrossRef

51.

Cho SC, Hwang JW, Kim BN, Lee HY, Kim HW, Lee JS, Shin MS, Lee DS (2007) The relationship between regional cerebral blood flow and response to methylphenidate in children with attention-deficit hyperactivity disorder: comparison between non-responders to methylphenidate and responders. J Psychiatr Res 41:459–465PubMedCrossRef

52.

Schweitzer JB, Lee DO, Hanford RB, Tagamets MA, Hoffman JM, Grafton ST, Kilts CD (2003) A positron emission tomography study of methylphenidate in adults with ADHD: alterations in resting blood flow and predicting treatment response. Neuropsychopharmacology 28:967–973PubMed

53.

Sabate E (2003) Adherence to long-term therapies: evidence for action. World Health Organisation, Geneva. http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf

54.

Hodgkins P, Sasane R, Christensen L, Harley C, Liu F (2001) Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr Med Res Opin 27:53–62CrossRef

55.

Christensen L, Sasane R, Hodgkins P, Harley C, Tetali S (2010) Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 26:977–989PubMedCrossRef

56.

Adler LD, Nierenberg AA (2010) Review of medication adherence in children and adults with ADHD. Postgrad Med 122:184–191PubMedCrossRef

57.

Caisley H, Mueller U (2012) Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: a systematic review. Eur Psychiatry 27:343–349PubMedCrossRef

58.

Kooij JJ, Rösler M, Philipsen A, Wächter S, Dejonckheere J, van der Kolk A, van Agthoven M, Schäuble B (2013) Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial. BMC Psychiatry 13:36PubMedCrossRefPubMedCentral

59.

Sobanski E, Retz W, Fischer R, Ose C, Alm B, Hennig O, Rösler M (2014) Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate. Eur Psychiatry 29:324–330PubMedCrossRef

60.

Miller TW, Nigg JT, Faraone SW (2007) Axis I and II comorbidity in adults with ADHD. J Abnorm Psychol 116:519–528PubMedCrossRef

61.

Sobanski E, Brüggemann D, Alm B, Kern S, Deschner M, Schubert T, Philipsen A, Rietschel M (2007) Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 257:371–377PubMedCrossRef

62.

Ollendick TH, Jarrett MA, Grills-Taquechel AE, Hovey LD, Wolff JC (2008) Comorbidity as a predictor and moderator of treatment outcome in youth with anxiety, affective, attention deficit/hyperactivity disorder, and oppositional/conduct disorders. Clin Psychol Rev 28:1447–1471PubMedCrossRef

63.

Wilens TE (2004) Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 27:283–301PubMedCrossRef

64.

Cunill R, Castells X, Tobias A, Capellà D (2014) Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol. doi:10.1177/0269881114544777

65.

Robison RJ, Reimherr FW, Gale PD, Marchant BK, Williams ED, Soni P, Halls C, Strong RE (2010) Personality disorders in ADHD Part 2: the effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD. Ann Clin Psychiatry 22:94–102PubMed

66.

Torgersen T, Gjervan B, Nordahl HM, Rasmussen K (2012) Predictive factors for more than 3 years’ duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study. J Clin Psychopharmacol 32:645–652PubMedCrossRef

67.

Ginsberg Y, Lindefors N (2012) Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. Br J Psychiatry 200:68–73PubMedCrossRef

Titel: Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD)
verfasst von: Wolfgang Retz
Petra Retz-Junginger
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe Sonderheft 1/2014
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-014-0542-4

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD)

Abstract

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2014

Prediction and prevention of psychosis: current progress and future tasks

Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects

A perfect match: noninvasive brain stimulation and psychotherapy

Selected issues of the DGPPN Congress in 2013

Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer’s disease

Interaction among childhood trauma and functional polymorphisms in the serotonin pathway moderate the risk of depressive disorders

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie